首页> 外文期刊>Bulletin of the Hospital for Joint Diseases >The Cost Effectiveness of Birth-Cohort Hepatitis C Screening During Pre-Admission Testing for Elective Procedures at a Single Specialty Orthopedic Hospital
【24h】

The Cost Effectiveness of Birth-Cohort Hepatitis C Screening During Pre-Admission Testing for Elective Procedures at a Single Specialty Orthopedic Hospital

机译:在单一特种矫形医院选修程序预处理测试中出生 - 队乙型肝炎筛选的成本效益

获取原文
获取原文并翻译 | 示例
           

摘要

In 2012, the Centers for Disease Control and Prevention issued a recommendation for hepatitis C screening of adults born between 1945-1965. Our institution incorporated birth-cohort screening into its pre-admission testing program for elective orthopedic procedures on February 3, 2015. The goal of this study was to report the results and costs of pre-admission birth-cohort hepatitis C screening at our institution from February 3, 2015, to January 27, 2017. A total of 11,659 elective inpatient procedures were scheduled during this time and 97.8% of eligible patients were screened. Nine patients with active infection were identified, and four were successfully treated. Costs were calculated using time-driven activity-based costing. The total screening cost per successfully treated patient was $36,930.02. Since patients were not routinely screened at our institution before this intervention, our 97.8% screening capture rate demonstrates that pre-admission testing for elective procedures is a novel, yet effective and underutilized way, to engage "baby boomers " in screening.
机译:2012年,疾病控制和预防中心发布了1945 - 1965年之间出生于1945年至1965年之间成人的丙型肝炎筛查的建议。我们的机构在2015年2月3日将出生 - 队员筛选进入其预处理骨科手术预处理检测计划。本研究的目标是报告我们的机构预备出生 - 缔约方审查的结果和成本2015年2月3日,到2017年1月27日。在此期间,共设定了11,659名选修住院内容,举办了97.8%的符合条件的患者。鉴定了9例活性感染患者,并成功治疗了四个。使用基于时间驱动的活动的成本计算来计算成本。每成功治疗患者的总筛查成本为36,930.02美元。由于患者在本干预之前没有经常筛选到我们的机构,我们的97.8%的筛选率展示了选择性程序的入场前测试是一种新颖,但有效和未充分利用的方式,以便在筛选中聘用“婴儿潮一代”。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号